Vincristine sulfate

For research use only.

Catalog No.S1241 Synonyms: Leurocristine

46 publications

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vincristine sulfate has been cited by 46 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M3fDVmNmdGxiVnnhZoltcXS7IFHzd4F6 MX:wMVAvPSEQvF2= NGG3U4ozPCCq NEHlcZJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2S0NlI2PjZ|N{[5
HepG2-HBV1.1 NEe5UoFCeG:ydH;zbZMhSXO|YYm= M4HmcFAuOC53IN88US=> M3rHXFI1KGh? NVvHcINlcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NI[3R3ozPTZ4M{e2PS=>
HepG2.2.15 M3\BWmZ2dmO2aX;uJGF{e2G7 NGrudG0xNjFizszN Mn\DNlQhcA>? MnXldJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u MmPhNlU3PjN5Nkm=
HepG2-HBV1.1 NXHhXVdbTnWwY4Tpc44hSXO|YYm= NIPBSXMxNjFizszN NH;zSIkzPCCq MVfwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= NHXqTY4zPTZ4M{e2PS=>
HepG2-HBV1.1 NU\SbnNUTnWwY4Tpc44hSXO|YYm= NIfiXJgxNjFizszN NYLWXndOPDhiaB?= M3vxfpBzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>? NXHqblZIOjV4NkO3Olk>
HepG2-HBV1.1 M2D1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzYPYgxNjFizszN M{e5dVEuPSCm Mn7HbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= NHvjXFEzPTZ4M{e2PS=>
HepG2-HBV1.1 NXXmcJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH1W|cxNjFizszN NH7lZXUyNTViZB?= MojobY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MoPqNlU3PjN5Nkm=
HepG2-HBV1.1 M3TqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlEh|ryP MWKxNk04OiCq M1zSVYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> NFfCfWYzPTZ4M{e2PS=>
HepG2-HBV1.1 NGH4e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMlEh|ryP M1Lzb|EzNTd{IHi= M1\SV4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> NVfGe4U1OjV4NkO3Olk>
Raji MoTGSpVv[3Srb36gRZN{[Xl? NXH1R2pVOC53wrFOwG0> NXf1WIh6PzJiaB?= MVPhZo9tcXOqZYOgZZV1d3CqYXf5xsA> MVyyOVQ1PjN5Nx?=
SK-MEL-28  M3PDVGZ2dmO2aX;uJGF{e2G7 MXGzNEBvVQ>? NELiVZk3KGh? NFHWVW5qdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= MXKyOVMyOzBzMB?=
H157 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwMEOgxtEhOC5yNDDtbZUzVQ>? MU[yOVI2PzlzMR?=
Jurkat M1jicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXadWdrOS1|IH7N M{WyZ|Q5yqCq NITlcVBFVVOR NXLrfJB5\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NVnq[pg4OjVzNU[xOFY>
CEM MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXoNU0{KG6P M1z1O|Q5yqCq MlnESG1UVw>? M2PrXIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> M2PR[lI2OTV4MUS2
P12 M{DUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL0NU0{KG6P MYe0POKhcA>? MmLjSG1UVw>? MoDT[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> M2\4N|I2OTV4MUS2
KB Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n0VWlEPTB;MD6wNFQ6KMLzIECuNFAxOSEQvF2= NXe1e2VwOjVyNUi1NlY>
KBv200 (ABCB1) M3\Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= NH:z[oUzPTB3OEWyOi=>
SUDHL6  M16wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvybpMy6oDLzszN NYCyOldtPDhxN{KgbC=> MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSC|aXfubYZq[2GwdHz5 NWjNRpl{OjR7NkG2NFQ>
SUDHL6  NH7LXYNHfW6ldHnvckBCe3OjeR?= MnLvNgKBkc7:TR?= MXy3NkBp NEnkOY1qdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D NFXQToUzPDl4MU[wOC=>
HCT-116 NYPXbpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvaZYxIUTVyPUWgcm0> NYHpXo57OjR7Mke4OVc>
SKNBe2C Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXDTWM2OD1|Mj64xtE1NjBibl2= Ml6wNlQ6OjF7MkC=
IGNR91 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi3O4RKSzVyPUK0MlPDuTFwNzDuUS=> NHzQO3AzPDl{MUmyNC=>
SKNAS NF\LPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNdMxNE4zKG6P MXmyOFkzOTl{MB?=
LAN1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwM9MxNE4zKG6P NVfUenppOjR7MkG5NlA>
SHSY5Y MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tXW5KSzVyPUiuNuKyOC54IH7N NVrKUWNDOjR7MkG5NlA>
A549-WT MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? MV6yOFg2QDh{Nx?=
A549-R NYXtXmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQPZlyUUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N NYrHXnRmOjR6NUi4Nlc>
MCF-7-WT NWW4cpBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0ZXRrUUN3ME2xO{44PTJiwsGgNE4zOThiIH7N NHrseI8zPDh3OEiyOy=>
MCF-7-R M13OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PPOWlEPTB;NT61N|khyrFiMD6xOFQhKG6P NIfHV4YzPDh3OEiyOy=>
A549-R NFn2fVlEgXSxdH;4bYNqfHliQYPzZZk> M1PHRWlEPTB;MUKuNVc5KMLzIECuN|M{KG6P NFL5UpkzPDh3OEiyOy=>
MCF-7-R NYT6OHp7S3m2b4TvfIlkcXS7IFHzd4F6 MU\JR|UxRTVwNUO5JOKyKDBwMUS0JI5O NGW4epkzPDh3OEiyOy=>
SW620 M17sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTdwOECgxtEhOC5yODDuUS=> NWPkRXpoOjR5Mk[3N|k>
SW620/AD300 Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVizblRUUUN3ME25NFkvPjBiwsGgPE46OSCwTR?= NEHtUoYzPDd{NkezPS=>
HEK293/pcDNA3.1 NH7OdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvJTWM2OD1zLkS1JOKyKDBwMkCgcm0> M1KzUlI1PzJ4N{O5
HEK293/ABCC1 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzp[mxWUUN3ME2xPU4zQSEEsTCyMlA5KG6P NFjmNZYzPDd{NkezPS=>
TCC NGS3R2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmyOEBp NHzDNXZKSzVyPUewJI5O NXGzc45COjR5MU[5OFQ>
TCC NV\rdZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK0PEBp NEPHXWJKSzVyPUWwJI5O NHvTOWIzPDdzNkm0OC=>
HepG2/ADM MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TIOmlEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP NYTyd4JrOjR5MES1OVY>
HepG2 NYPPdHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjzUW5KSzVyPUCuNFEyPcLzMD6wNFE4KM7:TR?= NX\JdIQ3OjR5MES1OVY>
MCF-7/ADR M{PpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nCbGlEPTB;ND60PFI3yrFyLkKwO|Ah|ryP MXuyOFcxPDV3Nh?=
MCF-7 M2jRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEG1PeKyOC5yME[yJO69VQ>? Mn76NlQ4ODR3NU[=
A-172  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;4OYwxNjIEoN88US=> NGDFR2YzPC95MjDo NXzYZpd3cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NHzFXWMzPDV|MEKzOS=>
U-251MG M4fYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnHNE4yyqEQvF2= M3O1cVI1Nzd{IHi= NWruOHJKcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NGHmR4YzPDV|MEKzOS=>
DLD-1 NUntWXJTTnWwY4Tpc44hSXO|YYm= MoPkNVAxKG6P MofxOFghcA>? M125TpBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? NYf3[JpGOjR2MEO0OVM>
CCD18Co M{XpZ2Z2dmO2aX;uJGF{e2G7 Mo\CNVAxKG6P NUDC[XNJPDhiaB?= MkL2dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh MWWyOFQxOzR3Mx?=
DLD-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonyNE0yODByIH7N NWOwS4tKPDhiaB?= MWLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXPkPYlROjR2MEO0OVM>
CCD18Co MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrrNE0yODByIH7N NVnTVYJmPDhiaB?= MX\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NYi2W3ZFOjR2MEO0OVM>
HepG2 NGfHRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXnNlQhcA>? NGPLTVdKSzVyPUWyMlXjiIoQvF2= M33HcVI1OzRzNki4
HEK293/pcDNA3.1 NIniU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDlUFVLUUN3ME2wMlAxPMLzMD6wNFA{KM7:TR?= NFzhOnkzPDJ6NEe4Ny=>
HEK293/MRP1 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HpUGlEPTB;MD6wOVXDuTBwMEGyNEDPxE1? NYTYT206OjR{OES3PFM>
Ramos MmHTRZBweHSxc3nzJGF{e2G7 NGPzU5Qz6oDLzszN MV[0PEBp NXrQOIZxcW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| MVGyOFI2PjR7MR?=
NCI-H1299/pcDNA3 NH3NbldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUSwMVIxKG6P NIjxU4I6PiCq M1X2bolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXeyOFE4PzBzMh?=
H1299/ICAM-3 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVmwMVIxKG6P NIjSfmc6PiCq NXnEN2JYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NWXSbGoyOjRzN{ewNVI>
NCI-H1299/pcDNA3 NX3DSZFKTnWwY4Tpc44hSXO|YYm= MXGxM|UwOTBxMkFCpI5O MWS5OkBp MWjpcoR2[2W|IHPs[YF3[WenIH;mJINie3Cjc3XzMVMtKDhuIEmsJIFv\CCSQWLQ MWqyOFE4PzBzMh?=
H1299/ICAM-3 MW\GeY5kfGmxbjDBd5NigQ>? M1;wdlEwPS9zMD:yNOKhdk1? Mm\DPVYhcA>? NGfqR5lqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MWKyOFE4PzBzMh?=
W1 NVnobnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMECzNkDPxE1? MljtNlQyPDBzN{[=
W1VR NE[3SlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTVSIV{UUN3ME2wMlA2PiEQvF2= NHO1U5czPDF2MEG3Oi=>
K562 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTxU|hKSzVyPUCuNFMzKMLzIECuNFAyKCEQvF2= NXPVZmZYOjRzM{W5N|c>
K562/ADR M{K2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HQeGlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP NV61T202OjRzM{W5N|c>
K562 MmLsRZBweHSxc3nzJGF{e2G7 MUmwMlMh|ryP MVSyOEBp NF;IcJZqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 Ml[1NlQyOzV7M{e=
K562/ADR M{LvcWFxd3C2b4Ppd{BCe3OjeR?= M{\WeVMh|ryP NHS2[4czPCCq M{nETolv\HWlZYOgZZBweHSxc3nz Mn\hNlQyOzV7M{e=
A549 M4HyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnGblRHUUN3ME2wMlExKMLzIECuNFMh|ryP M1rzS|I{QTdzMEe1
K562 M1\jcWNmdGxiVnnhZoltcXS7IFHzd4F6 MXizMlc26oDVNkFCpI5O MXW3NuKhcMLi NUGyVllmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MnO5NlM5Pzd{MkO=
lucena Mn70R4VtdCCYaXHibYxqfHliQYPzZZk> MVizMlc26oDVNkFCpI5O MWW3NuKhcMLi M12xeo5wKGWoZnXjeC=> M4LPcFI{QDd5MkKz
FEPS NYS1eGsxS2WubDDWbYFjcWyrdImgRZN{[Xl? M4fid|MvPzYkgKO2NOKhdk1? MV[3NuKhcMLi MlH5co8h\W[oZXP0 Mn3VNlM5Pzd{MkO=
A2780 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwNTDtUS=> NXHE[JJTOjN6MkmyNFM>
ACHN NF7WUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXkS|VKSzVyPECuNUBuVQ>? MYOyN|gzQTJyMx?=
U-937 NEHRU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:5OZlKSzVyPEO0JI5O NHHjfngzOzh{OUKwNy=>
Jurkat NInTVVBCeG:ydH;zbZMhSXO|YYm= NHjORXU2yqEQvHevcYzDqA>? NYDq[XZNOjRiaB?= NXO4cYY2cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NFG1dYgzOzhzMESwPS=>
Jurkat MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS1xsDPxGdxbX|CpC=> NI[wTY8zPCCq MoHDZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn NFPKcngzOzhzMESwPS=>
Hep-2 NXj1SVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTEd2lsUUN3ME2wMlA1yrFyLkCxJO69VQ>? NFzoWYEzOzd6MESyOC=>
Hep-2/v MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jVTWlEPTB;MT64xtExNjJyIN88US=> M1H2PVI{PzhyNEK0
SGC-7901 NF3nOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX0bJBvOC1zMDFOwIcwdWx? MoPvNlQwPDhxN{KgbC=> NX\XUIh{cW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MnniNlM4PDN3N{K=
SGC-7901/VCR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:wMVExKM7:Zz;tcC=> MW[yOE81QC95MjDo NHXpNo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MUSyN|c1OzV5Mh?=
SGC-7901 MVvBdI9xfG:|aYOgRZN{[Xl? M37NSYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? M1myblI{PzR|NUey
SGC-7901/VCR NI\tNIJCeG:ydH;zbZMhSXO|YYm= MnfmbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NHjVcZIzOzd2M{W3Ni=>
KB-3-1 NHjlZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwNk[gxtEhOC5zNkKg{txO M{LYVlI{Pjd|NES1
KB-C2 M2HvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP M3zh[|I{Pjd|NES1
KB-3-1 NWfyPIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfCTWM2OD1zLkK2JOKyKDBwMEK3JO69VQ>? NUPxPW8xOjN4N{O0OFU>
KB-V1 NEDZdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1fGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP NGLBc3kzOzZ5M{S0OS=>
HEK293/pcDNA3.1 NYDnSpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\rS3BKSzVyPUK0MlEhyrFiMD6yNFQh|ryP M4fhOlI{Pjd|NES1
HEK293/ABCB1 NWPO[mFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1|NUGyMlghyrFiM{e4MlM6OSEQvF2= M2[yTFI{Pjd|NES1
A549/EGFP  M{TkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ZTlAvODFvMUCwNEDPxE1? MVTJR|UxRTh4LkegxtEhOjlwMTFOwG0> MlLoNlM3OzR{OEK=
A549/Slug NG\uc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXz[oE3OC5yMT2xNFAxKM7:TR?= MVPJR|UxRTlwNzFCtUA{NjFizszN NYWyZY1NOjN4M{SyPFI>
JFCR39  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexJOK2VQ>? M{\1VFI1KGh? NInVfJdFVVOR NE[zboNu[XKtZXTsfUBqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDHNk9OKHCqYYPlJINmdGy| MlHmNlM2QTh{N{[=
A549 NIrZb3NHfW6ldHnvckBCe3OjeR?= M{XNVVExOCCwTR?= NViwU2xGOTZiaB?= M1f1N2ROW09? M2\0PIxm[WS|IITvJIEhdG:|czDv[kBucWO{b4T1ZpVt\XN? NUPKOFZoOjN3OUiyO|Y>
SGC7901 NEDXXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fF[2lEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> MkXNNlM2PjR2OEK=
SGC7901/LV-NC MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm4XVRkUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? M1uyfFI{PTZ2NEiy
SGC7901/LV-SGO1 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwM{dihKnDueLCiUCuN|ch|rypL33s MY[yN|U3PDR6Mh?=
SGC7901/VCR M3;TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rObGlEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t MmroNlM2PjR2OEK=
SGC7901/VCR-NC NHezSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CyfmlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t NUfncpA2OjN3NkS0PFI>
SGC7901/VCR-si-SGO1 NHfKbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s M4DONVI{PTZ2NEiy
SGC7901/ADR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTdwOEZihKnDueLCiUCuOlQh|rypL33s M4LGTFI{PTZ2NEiy
SGC7901/ADR-NC NX\zbXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHYeXBKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MWWyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 NHjifYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljPTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> NVvwXpZpOjN3NkS0PFI>
SH-SY5Y  M1PETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XuVVAvODBzLUGwJO69VQ>? NWP5W3JYOjRiaB?= MojoTWM2OD1yLkGxN:KyOC5yMUKg{txO MV:yN|EzQTB4NR?=
SH-SY5Y  M3P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\mR25nOC5yMEGtNVAh|ryP NHuwNVA1QCCq M4jLTGlEPTB;MD6wO|jDuTBwMEC5JO69VQ>? MXyyN|EzQTB4NR?=
SH-SY5Y  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHnZ2FmOC5yMEGtNVAh|ryP MlLrO|IhcA>? MlztTWM2OD1yLkC1NeKyOC5yMEig{txO Mni3NlMyOjlyNkW=
SH-SY5Y MVPBdI9xfG:|aYOgRZN{[Xl? MnvvNE4yKM7:TR?= MV:wMVI1KGh? NVO0[I1icW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> NHrFOmkzOzF{OUC2OS=>
SH-SY5Y NIniTVdCeG:ydH;zbZMhSXO|YYm= NEfseGwxNjFizszN NX7rdXJVOC1{NDDo NXPDPXkzcW6mdXPld{BucXSxdHnjJIFzemW|dNMg MoTrNlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine
Smiles CCC1(O)CC2CN(CCC3=C([NH]C4=C3C=CC=C4)C(C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)C7C(O)(C(OC(C)=O)C8(CC)C=CCN9CCC67C89)C(=O)OC)C1.O[S](O)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID